MIRM
What one share of Mirum Pharmaceuticals holds
Pharmaceutical Preparations
We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI® (chenodiol) tablets (“Ctexli”).
Mirum Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $11.02 |
|---|---|
| Profit | −$15.33 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$4.08 |
| Cash and investments | $5.11 |
| Debt | $11.58 |
| Book value | −$0.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$4.58 | $0.02 | −$3.45 | — | $5.77 |
| 2020 | $0.00 | −$4.09 | $0.01 | −$3.54 | — | $5.78 |
| 2021 | $0.63 | −$2.77 | $0.00 | −$4.38 | — | $3.93 |
| 2022 | $2.27 | −$4.02 | $0.01 | −$3.54 | — | $3.84 |
| 2023 | $4.56 | −$4.00 | $0.00 | −$1.74 | — | $5.32 |
| 2024 | $7.09 | −$1.85 | $0.02 | $0.20 | — | $4.67 |
| 2025 | $10.39 | −$0.47 | $0.02 | $1.09 | — | $6.06 |